DIRS.INFO The most relevant business & tech news

☆ Stocks making the biggest moves premarket: Apple, Amgen, Cloudflare and more
▼ + stars: | 2024-05-03 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +3 min

Hershey — Shares of the chocolate confectionary maker added about 1% after Hershey posted a first-quarter earnings beat. Hershey's $3.25 billion revenue also beat the $3.11 billion consensus. Amgen — Shares soared 13% after the biotech firm posted a first-quarter earnings and revenue beat. Cloudflare — The stock continued to sink, plunging 12% after reporting weak full-year guidance, although Cloudflare posted a first-quarter earnings and revenue beat. However, Coinbase's first-quarter revenue of $1.64 billion beat the $1.34 billion consensus, according to LSEG.

Persons: Hershey, LSEG, Apple, Eli Lilly, Cloudflare, Expedia, Piper Sandler, Fortinet, FactSet, Jefferies, Coinbase's, Benjamin Nolan, — CNBC's Brian Evans, Michelle Fox, Hakyung Kim, Tanaya Macheel Organizations: Hershey —, Apple, Novo Nordisk, BMO Capital Markets, Revenue, Arista Networks, Arista, LSEG . Union Pacific, JPMorgan Locations: billings, LSEG, Stifel

☆ Stocks making the biggest moves midday: Apple, Expedia, Block, Live Nation and more
▼ + stars: | 2024-05-03 | by ( Hakyung Kim | ) www.cnbc.com time to read: +3 min

Check out the companies making headlines in midday trading: Apple — The tech giant jumped more than 6% after announcing it would repurchase $110 billion in shares . That topped analysts' estimates for earnings of $1.50 per share on revenue of $90.01 billion, per LSEG. Block — The payment services provider added 1% after posting first-quarter results that beat analysts' expectations. Live Nation Entertainment — Shares jumped 9% on the back of better-than-expected first-quarter revenue. However, the company beat analysts' expectations for the first quarter.

Persons: LSEG, Piper Sandler, FactSet, Eli Lilly, Cloudflare, Jefferies, —, Alex Harring, Lisa Kailai Han, Michelle Fox, Pia Singh Organizations: Apple, Management, Wall Street, BMO Capital Markets, Expedia, Holdings, bullish Bank of America, Novo Nordisk, Arista Networks, Arista Locations: Thursday's, billings

☆ Here are Friday's biggest analyst calls: Apple, Target, Coinbase, Berkshire Hathaway, Estee Lauder & more
▼ + stars: | 2024-05-03 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

JPMorgan upgrades Williams-Sonoma to neutral from underweight JPMorgan said in its upgrade of the stock that the home furnishings category is stabilizing. "We are downgrading shares of EXPE to Mkt Perform from OP with a target price of $145 vs. $165 previously." JPMorgan upgrades Joby to neutral from underweight JPMorgan said its bear thesis has largely played out for the aviation company. Guggenheim reiterates Target as buy Guggenheim said investors should buy the dip in shares of Target . Morgan Stanley downgrades Estee Lauder to equal weight from overweight Morgan Stanley said it sees a slower recovery for shares of Estee Lauder .

Persons: Stifel, Wells, Truist, OLLI, Guggenheim, Tim Cook, William Blair, Amgen, Jefferies, We've, Ari sta, it's, Morgan Stanley downgrades Estee Lauder, Morgan Stanley, Estee Lauder, TD Cowen, Parsons, Bernstein, Oppenheimer, CFRA, Berkshire Hathaway Organizations: RBC, FTAI Aviation, Pacific, Union Pacific, JPMorgan, Williams, WSM, BMO, Bank of America, Apple, Kiniksa Pharmaceuticals, JOBY, Guggenheim, Target, Citi, MCW, Arista, PSN, Avidity, ~$ Locations: Sonoma, EXPE, GEICO

☆ This rare muscle disease play can rally more than 50%, BofA says
▼ + stars: | 2024-05-03 | by ( Alex Harring | ) www.cnbc.com time to read: +2 min

Avidity Biosciences stock has more room to run thanks to the company's pipeline of multiple treatments for rare muscle disorders, according to Bank of America. Avidity has a therapeutic platform — antibody oligonucleotide conjugates — that was well-received at the time it went public in 2020, Meacham said. But shares were hurt by a clinical hold on Avidity's leading program for treating an uncommon muscle disorder, DM1. The program, tested in the Marina trial, recently saw long-term data that has "helped lift that key overhang on the stock," Meacham said. Those catalysts are tied to two other drugs in the muscle disorder space that are expected to report data this year, according to Meacham.

Persons: Geoff Meacham, Meacham Organizations: Biosciences, Bank of America Locations: San Diego, Thursday's

Check out the companies making headlines in after-hours trading: Apple — The iPhone maker advanced 7% as it announced a $110 billion share repurchase and a top- and bottom-line beat. That surpassed analysts' estimates for earnings of $1.50 per share on revenue of $90.01 billion, per LSEG. Expedia posted a beat on first-quarter revenue, which came in at $2.89 billion, surpassing analysts' estimates of $2.81 billion, per LSEG. Block reported adjusted earnings of 85 cents per share on revenue of $5.96 billion in the first quarter. Those results beat analysts' estimates for earnings of 72 cents per share and revenue of $5.82 billion, per LSEG.

Persons: Expedia, Amgen, LSEG, Fortinet, Cloudflare, DaVita, FactSet, —, Christina Cheddar, Berk Organizations: Apple Locations: billings

☆ Moderna loses less than expected as Covid vaccine sales beat estimates, cost cuts take hold
▼ + stars: | 2024-05-02 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Moderna on Thursday posted a narrower-than-expected loss for the first quarter as the company's cost-cutting efforts took hold and sales of its Covid vaccine, its only commercially available product, topped estimates. The biotech company booked first-quarter sales of $167 million, with revenue from its Covid shot dropping roughly 90% from the same period a year ago. The company reiterated its full-year 2024 sales guidance of roughly $4 billion, which includes revenue from its RSV vaccine. For the first quarter, Mock said the company is "more encouraged by what we're seeing from a productivity perspective" than the higher sales of its Covid vaccine. Cost of sales was $96 million for the fourth quarter, down 88% from the same period a year ago.

Persons: we've, Stéphane Bancel, Jamey Mock, Mock, OpenAI Organizations: Moderna, LSEG, CNBC, Research, Mock, Merck Locations: Moderna, U.S, America

☆ Stock futures rise after Apple reports, traders look to April payrolls data: Live updates
▼ + stars: | 2024-05-02 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Futures tied to the Dow Jones Industrial Average gained 212 points, or 0.55%. S&P 500 futures rose nearly 0.3%, while Nasdaq 100 futures advanced about 0.5%. In extended trading, Apple advanced more than 6% after it announced a $110 billion share repurchase and a top -and bottom-line beat. The S&P 500 popped 0.91%, while the Dow gained 0.85%. The S&P 500 is off by 0.7% week to date, while the Nasdaq is down nearly 0.6%.

Persons: Cloudflare, Dow, Jerome Powell, Sonu Varghese, payrolls, Dow Jones Organizations: New York Stock Exchange, Stock, Dow Jones Industrial, Nasdaq, Apple, Biotech Amgen, Dow, Carson Group Locations: New York City, U.S

☆ A millennial couldn't afford the Mounjaro weight-loss drug so he started secretly working 2 remote jobs. He's on track to make $166,000 this year and says he's lost 45 pounds.
▼ + stars: | 2024-05-01 | by ( Jacob Zinkula | ) www.businessinsider.com time to read: +6 min

A millennial in California is secretly working a second remote job so he can afford weight-loss drugs. AdvertisementLast August, George decided he wanted to try to work a second remote job — and not tell his employers he was job juggling. He was able to afford Mounjaro and said he's dropped 45 pounds — from 220 lbs to 175 lbs — since he started taking it in October. AdvertisementAfter a roughly monthlong search, he started his second job and was able to afford Mounjaro. Are you working multiple remote jobs at the same time and willing to discuss details about your pay and schedule?

Persons: Zepbound, —, George, Eli Lilly, he's, George hasn't, it's Organizations: Service, FDA, Nordisk's Ozempic, Business Locations: California, Mounjaro

☆ Citi names 3 biotech stocks to play a growing $2.9 billion opportunity — giving one about 50% upside
▼ + stars: | 2024-05-01 | by ( Weizhen Tan | ) www.cnbc.com time to read: +2 min

The outlook is starting to look bright for biotech stocks, according to some. With markets now expecting the first rate cut to be in September rather than June or July, as previously thought, biotech stocks could start to do well. Biotech encompasses many different areas, but Citi has identified one with a $2.9 billion market — which it says is set for even more growth. It gave CSL a price target of $305, or nearly 11% potential upside. It gave Intellia a price target of $31, or 49% potential upside.

Persons: Morgan Stanley, Garadacimab, Ionis, Citi Organizations: Biotech, Citi, Ionis Pharmaceuticals, Intellia Therapeutics, CSL, Intellia

☆ This $119 houseplant is bioengineered to remove harmful air pollution in your home.
▼ + stars: | 2024-04-30 | by ( Ellyn Lapointe | ) www.businessinsider.com time to read: +9 min

Biotech company Neoplants just released the first houseplant grown to reduce indoor air pollution. Neo P1 can remove 30 times more VOC's, harmful indoor pollutants, than a typical houseplant. This week, the France-based biotech company Neoplants released the first houseplant bioengineered to remove harmful chemicals from indoor air. AdvertisementUnpacking the Neo P1 systemThe Neo P1 system comes with a marble queen pothos potted in a specially designed "shell," and a six-month supply of power drops. AdvertisementStriving for sustainabilityEvery part of the Neo P1 air purifying system is manufactured in the US.

Persons: —, you'd, Glenn Morrison, Patrick Torbey, Lionel Mora weren't, Mora, Torbey, Morrison, Neoplants, Jennifer Brophy, " Mora, it's, we'll Organizations: Biotech, Neoplants, Service, American Lung Association, University of North, Business, Stanford University, MIT Tech Locations: France, University of North Carolina, Torbey, VOCs, Neoplants, Paris

☆ Here are Tuesday's biggest analyst calls: Nvidia, Tesla, Apple, Live Nation, Boeing, Coinbase, Amazon & more
▼ + stars: | 2024-04-30 | by ( Michael Bloom | ) www.cnbc.com time to read: +5 min

Bank of America reiterates Tesla as buy Bank of America said it's standing by its buy rating on the electric-vehicle maker. "We maintain our Buy rating and raise our PT from $1100 to $1,150." "We are initiating coverage of Live Nation with a Buy rating and $120 price target." "We are initiating coverage on EE with an Overweight rating." "We are initiating coverage of Integral Ad Science with a Buy rating and a $15 price target."

Persons: Tesla, TSLA, Morgan Stanley, Oppenheimer, Raymond James, Mizuho, Airbnb, Coinbase, Needham, Stephens, Jefferies, Ralph Lauren, Chegg Organizations: Argus, Boeing, " Bank of America, Bank of America, UBS, Nvidia, Dyne, JPMorgan, Catalyst Watch, Apple, Mizuho, Citi, BTC, Ethereum, Paramount, CBS, Deutsche Bank, Deutsche, Excelerate Energy, Stephens, Barclays, UMB, Corp, Contineum Locations: Base, Kansas City

☆ Inside the investing strategy of Hunterbrook Capital, the news-driven hedge fund. Can it succeed in a ruthless industry?
▼ + stars: | 2024-04-29 | by ( Bradley Saacks | ) www.businessinsider.com time to read: +6 min

Small team, limited scopeThe hedge fund makes trades based solely on news from Hunterbrook Media, its media sister company, sometimes getting advanced copies of the articles and placing trades before publication. AdvertisementThe hedge fund, however, has just one sole full-time employee. Before a story is published on Hunterbrook Media, the firm's general counsel reviews it to make sure there's not any insider information — such as leaked earning figures — in it. AdvertisementIf the general counsel and the executives green light the story to be shared, then it goes to the hedge fund — in other words, Dunlevie and Horwitz — prepublication. Opportunities few and far between so farInvestigations from Hunterbrook Media so far have less than a 50% hit rate on turning into trades for the hedge fund.

Persons: —, Nate Anderson's Hindenburg, Carl Icahn's, Nathaniel Horwitz, Matt Murray, Paul Steiger, Bethany McLean, That's, Courtney Dunlevie, Horwitz, Sam Koppelman, Brian Koppelman, Dunlevie, Horwitz — prepublication, isn't, It's Horwitz, Matt, Pulitzer, Tony Horwitz, Geraldine Brooks, Cash, Hunterbrook, Marc Lasry, David Fialkow, Matt Cherwin, we're, " Horwitz Organizations: Service, Business, Hunterbrook, Hunterbrook Media, Wall Street, Barclays, Commonstock, Phoenix Suns, Avenue Capital, Catalyst, JPMorgan Locations: Italian, Korean, Brazil

☆ ‘This is a unique time’: ARK Invest’s chief futurist tackles tech innovation from AI to robotics
▼ + stars: | 2024-04-27 | by ( Meredith Mutter | ) www.cnbc.com time to read: +1 min

ARK Invest's chief futurist lists five groups that should give tech investors an edge. "We believe that this is a unique time in technological economic history," he told CNBC's "ETF Edge" this week. Winton collaborates with ARK Invest CEO Cathie Wood to maintain the ARK Venture Fund (ARKVX), which allows investors to buy into the private technology space. "That's a real challenge a lot of public market investors don't have that long-term view," Winton added. The ARK Venture Fund is down more than 7% so far this year.

Persons: ARK, Brett Winton, CNBC's, Winton, Cathie Wood Organizations: ARK, ARK Venture, Epic, Therapeutics

One strategist, however is looking keenly at European equities, and notes that "Europe isn't a boring market." "You would hope that will translate through to the stock market in terms of company earnings growth in Europe. "While you might see some kind of short-term downturn, in the longer-term the picture is very positive for the sector," Field added. He sees value in payments, which he described as "one of the most undervalued parts of European financial services." The sector has trailed market performance, with valuations looking "interesting" over the last 12 months, Morningstar noted in its recent report.

Persons: Michael Field, Field, Morningstar Organizations: CNBC Pro, European Central Bank, Consumer, Swatch Group, Financial, Morningstar, ING Bank, Group, Health, Novo Nordisk Locations: U.S, Europe, Netherlands, British, Swiss

☆ Stocks making the biggest moves after hours: Alphabet, Microsoft, Snap, Intel and more
▼ + stars: | 2024-04-25 | by ( Yun Li | ) www.cnbc.com time to read: +2 min

Microsoft – The tech giant saw shares climb 4.5% in extended trading after the software maker posted fiscal third-quarter results that surpassed Wall Street's expectations. Snap – Shares soared more than 27% in afterhours trading after the social media firm reported first-quarter results that beat analysts' estimates. Intel reported earnings that beat Wall Street expectations, however. Dexcom reported adjusted earnings of 32 cents per share on revenue of $921 million in revenue. Those results surpassed the earnings of $1.10 per share and $2.2 billion in revenue anticipated by analysts polled by LSEG.

Persons: Dexcom, FactSet, Gilead, Skechers, L3Harris, Macheel, Darla Mercado Organizations: Microsoft, Intel, Gilead Sciences, LSEG Locations: LSEG .

☆ Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss
▼ + stars: | 2024-04-25 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, US, on Wednesday, Dec. 27, 2023. Bristol Myers Squibb on Thursday reported first-quarter revenue that topped expectations as its blockbuster blood thinner Eliquis and several new drugs posted sales growth. Two-thirds of savings are associated with drug research and development, Bristol Myers Squibb executives said during an earnings call on Thursday. Those deals come as Bristol Myers faces pressure to launch new drugs and offset the potential loss of revenue from top-selling treatments. Shares of Bristol Myers fell more than 1% in premarket trading Tuesday.

Persons: Bristol Myers, Samit Hirawat, Chris Boerner, Boerner, Revlimid Organizations: Bristol Myers Squibb, Bristol Myers, Karuna Therapeutics, SystImmune, Bristol, LSEG Locations: Cambridge, Cambridge , Massachusetts, Here's

☆ Biogen tops profit estimates as cost cuts take hold, Alzheimer's drug Leqembi launch picks up
▼ + stars: | 2024-04-24 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Biogen on Wednesday reported first-quarter profit that topped estimates as the company's cost-cutting efforts took hold and sales of its closely watched Alzheimer's drug, Leqembi, came in higher than expected. Biogen and Eisai 's Leqembi became the first drug found to slow the progression of Alzheimer's disease to win approval in the U.S. in July. Leqembi brought in about $19 million in sales for the quarter, up from the $10 million the drug generated last year. In February, Biogen CEO Chris Viehbacher told reporters that there were around 2,000 patients currently on Leqembi. Adjusting for one-time items, the company reported earnings of $3.67 per share.

Persons: Biogen, Leqembi, FactSet, Chris Viehbacher, LSEG Organizations: LSEG Locations: U.S

☆ Greenlight's David Einhorn builds new stake in this gambling name. Here's what else he bought
▼ + stars: | 2024-04-24 | by ( Adam Jeffery | ) www.cnbc.com time to read: +2 min

Greenlight Capital's David Einhorn continued to pick up new stocks in the first quarter, including Penn Entertainment , as the longtime value investor struggles to find opportunities in the volatile market. He established the stake at an average cost of $22.69 per share, but the stock has fallen to $17.44 as of Wednesday. Still, Einhorn said sports betting, if executed right, could take the shares much higher. "Were the market to credit PENN with merely 15% of DraftKings' value, that segment alone would be worth $20 per share." Q4 buyer's strike Einhorn had stopped building new stock positions at one point in the fourth quarter, saying he was on a "buyer's strike" due to worries about intensifying geopolitical risks.

Persons: Greenlight Capital's David Einhorn, Einhorn, PENN, he's, Greenlight, — CNBC's Leslie Picker Organizations: Penn Entertainment, CNBC, Barstool Sports, Cornell grad, Greenlight Capital, HP, Roivant Sciences, Liberty Global

Here's a rapid-fire update on all 33 stocks in Jim Cramer's Charitable Trust, the portfolio we use for the CNBC Investing Club. Broadcom : Broadcom's AI business, which includes co-designing custom chips for tech giants such as Club holding Alphabet, is booming. The newspaper reported April 12 that Salesforce was in talks to buy Informatica, which sent the Club holding's shares plunging. Wells Fargo : Another trim is due for our Wells Fargo position after a great run for the bank stock, Jim argued. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

Persons: Jim Cramer's, Jim, Johnson, Abbott, Andy Jassy, Bausch, Salesforce, Salesforce didn't, Tom Jorden, We've, It's, Walt Disney, Nelson Peltz's, Bob Iger's, Estee Lauder, there's, Eaton, We're, he's, Locker, he'd, Vimal Kapur, Linde, Eli Lilly, Eli Lilly's, TikTok, Joe Biden, Morgan Stanley, Morgan Stanley's, Ted Pick, Jensen Huang, Nikesh Arora, haven't, Laxman Narasimhan, Sands, Stanley Black, Decker, TJ Maxx, TJX, Wells, Jim Cramer, Angela Weiss Organizations: Jim Cramer's Charitable Trust, CNBC, Club, Apple, Abbott Laboratories, Johnson, Web Services, Broadcom, VMWare, GE Healthcare, GE, Bausch Health, Costco Wholesale, Costco, Street, Informatica, Coterra, DuPont De Nemours, DuPont, Walt, Disney, Ford, GM, Philips, Siemens, Google, Honeywell, Linde, Facebook, Meta, Microsoft, Nvidia, Investors, AMD, Oregon State University, Palo Alto Networks, UnitedHealth, Procter & Gamble, Constellation Brands, Constellation, Modelo, TJX, Marshalls, Home Goods, Wynn Resorts, Jim Cramer's Charitable, New York Stock Exchange, Afp, Getty Locations: China, Informatica, Ford, Estee, U.S, mater, Palo, Corona, Wells Fargo, Wells, Macao, New York City

☆ When Tesla shares rise — these 7 stocks have tended to rise too, according to recent history
▼ + stars: | 2024-04-24 | by ( Ganesh Rao | ) www.cnbc.com time to read: +2 min

Seven stocks in the S & P 500 tend to rise alongside Tesla shares, according to an analysis of recent data by CNBC Pro . The share price performances of these S & P 500 stocks were highly correlated to Tesla's last month. However, unlike Tesla's more than 30% plunge this year, these stocks have either remained flat or have relatively modest negative returns. A correlation of zero would indicate no statistical link between the EV automaker's stock and the share price of the seven companies. The consensus upside potential for the stocks listed above was derived from FactSet's poll of analysts covering each stock.

Persons: Elon Musk, weathers, — CNBC's Lora Kolodny Organizations: CNBC Pro, Juniper Networks, Seagate Technology, Tyler Technologies, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, IDEXX Laboratories, EV, CNBC Locations: U.S, lockstep

☆ Here are the portfolio's top 5 performing stocks since the March Monthly Meeting
▼ + stars: | 2024-04-24 | by ( Morgan Chittum | ) www.cnbc.com time to read: +7 min

Stocks hit a rough patch after the Club's March Monthly Meeting as Wall Street grappled with increasing odds of higher-for-longer interest rates. Here are our five top-performing stocks since the March Monthly Meeting. WFC YTD mountain Wells Fargo (WFC) year-to-date performance Wells Fargo led the way, with shares jumping 5.8% over the period. GOOGL YTD mountain Alphabet (GOOGL) year-to-date performance Alphabet stock rose 4.9% since the March Monthly Meeting, placing the Google parent in second place on the gainers list. EL YTD mountain Estee Lauder (EL) year-to-date performance Estee Lauder stock added 2.7% since the March Monthly Meeting, occupying the fourth spot on our list.

Persons: Stocks, Wells Fargo, Jim Cramer, Wells, Jim, he's, Lauder, Estee Lauder, Estee, Fabrizio Freda, Freda, Jim Cramer's, Dow, Spencer Platt Organizations: Dow Jones, Nasdaq, Club, Google, Big Tech, Palo Alto Networks, Bank of America, Citigroup, CNBC, Traders, New York Stock Exchange, Getty Locations: Wells, buybacks, Palo, Alto, New York City

☆ Grandmother Becomes Second Patient to Receive Kidney From Gene-Edited Pig
▼ + stars: | 2024-04-24 | by ( Roni Caryn Rabin | ) www.nytimes.com time to read: 1 min

A severely ill 54-year-old woman earlier this month became the second person to receive a kidney transplanted from a genetically modified pig, surgeons at NYU Langone Health in New York announced on Wednesday. The patient, who had both heart failure and kidney failure, was given the organ on April 12, just eight days after receiving a mechanical heart pump. Surgical teams at NYU Langone carried out the two procedures over the course of nine days. The kidney came from a genetically engineered pig provided by United Therapeutics Corporation, a biotech company. The pig carried a gene for producing a sugar called alpha-gal that had been “knocked out,” or blocked.

Persons: NYU Langone, Lisa Pisano, “ Organizations: NYU Langone Health, NYU, United Therapeutics Corporation Locations: New York, New Jersey

☆ Wells Fargo becomes bullish on this biotech company
▼ + stars: | 2024-04-24 | by ( Hakyung Kim | ) www.cnbc.com time to read: +1 min

Neurocrine Biosciences ' drug pipeline is turning a corner and the company will be "knocking on the doors of the large-cap club" soon, according to Wells Fargo. Bansal forecasts the company's congenital adrenal hyperplasia treatment, crinecerfont, will achieve $1.5 billion in peak sales, topping his prior $1.1 billion estimate. "We think [the] Crinecerfont [opportunity] is underappreciated as the Street is only giving credit for $500-$700M peak opportunity." Bansal said this drug could open "a whole new chapter" of a $1.2 billion peak sales opportunity. The NBI-'845 treatment could be "another blockbuster opportunity," Bansal said, citing the treatment's once-daily administration as a factor in his assessment.

Persons: Mohit, Bansal, Takeda, — CNBC's Michael Bloom Organizations: Biosciences Locations: Wells Fargo

☆ Danaher shares jump 7% as the turnaround in biotech spending finally arrives
▼ + stars: | 2024-04-23 | by ( Zev Fima | ) www.cnbc.com time to read: +8 min

Shares of Danaher popped more than 7% on Tuesday after the life sciences company delivered beats across its three main businesses — a sign the long-awaited turnaround in the biotech industry is finally here. Danaher Why we own it : Danaher is a best-in-class life sciences and diagnostics company, with a management team who have proven time and again their ability to find new ways to grow. The turnaround is now in effect, with bioprocessing orders up on a sequential basis. Within the segment, bioprocessing sales fell a "high teens" percentage, while discovery and medical declined 20% year over year. Diagnostics sales advanced 7.5% on a core basis to $2.53 billion.

Persons: Danaher, Blair, Beckman Coulter, Jim Cramer's, Jim Cramer, Jim, Igor Golovnov Organizations: LSEG, Bloomberg, Biotechnology, Management, CNBC, Getty Locations: bioprocessing, China, North America, Europe

☆ Here are Monday's biggest analyst calls: Apple, Nvidia, Tesla, Meta, Amazon, Microsoft, Spotify, Ferrari & more
▼ + stars: | 2024-04-22 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Morgan Stanley reiterates Apple as overweight Morgan Stanley lowered its price target on the stock to $210 per share from $220 but says it's sticking with Apple. Bank of America reiterates Amazon as buy Bank of America said it's bullish heading into Amazon earnings next week. Bank of America reiterates Tesla as neutral Bank of America said it's sticking with its neutral rating on Tesla shares. Morgan Stanley upgrades Alcoa to equal weight from underweight Morgan Stanley said it sees a more balanced risk/reward for shares of Alcoa. Bank of America reiterates Apple as buy Bank of America says Apple is a top pick at the firm.

Persons: Goldman Sachs, Goldman, Morgan Stanley, it's, Piper Sandler, Piper, Apple, Q, Q revs, Papa, Stifel, Papa John's, Jefferies, Mizuho, JPMorgan, Raymond James downgrades, Raymond James, TD Cowen, BRBR, BMO downgrades, Tesla, Oppenheimer Organizations: Nvidia, NVIDIA, RBC, Apple, Microsoft, Meta, Bank of America, JPMorgan, Cisco, Deutsche Bank, Realty Trust, Deutsche, Brands, BMO, of America, Alcoa, Kymera Therapeutics, " Bank of America Locations: Singapore, Asia, Brazil

Search resuls for: "Biotech"

25 mentions found